Gyre Therapeutics (NASDAQ:GYRE) Shares Down 12.5% – Time to Sell?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) shares fell 12.5% on Monday . The stock traded as low as $8.11 and last traded at $7.97. 99,280 shares were traded during mid-day trading, an increase of 17% from the average session volume of 84,647 shares. The stock had previously closed at $9.11.

Wall Street Analysts Forecast Growth

Separately, Noble Financial initiated coverage on Gyre Therapeutics in a research report on Tuesday, March 11th. They set an “outperform” rating on the stock.

Gyre Therapeutics Price Performance

The firm has a fifty day simple moving average of $11.16 and a two-hundred day simple moving average of $12.07. The firm has a market cap of $721.75 million, a price-to-earnings ratio of 154.20 and a beta of 1.93.

Gyre Therapeutics (NASDAQ:GYRE) last posted its quarterly earnings data on Monday, March 17th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.03). Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%. The company had revenue of $27.87 million for the quarter, compared to analyst estimates of $23.50 million.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. FMR LLC acquired a new stake in shares of Gyre Therapeutics during the third quarter worth about $47,000. Wells Fargo & Company MN lifted its stake in Gyre Therapeutics by 29.4% during the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock valued at $49,000 after acquiring an additional 913 shares during the period. Bank of America Corp DE boosted its holdings in shares of Gyre Therapeutics by 40.4% in the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after acquiring an additional 1,996 shares during the last quarter. Barclays PLC increased its stake in shares of Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after acquiring an additional 6,855 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in shares of Gyre Therapeutics by 11.1% during the fourth quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock worth $168,000 after purchasing an additional 1,389 shares during the last quarter. 23.99% of the stock is owned by institutional investors and hedge funds.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.